| GSK
to launch cancer drug Tykerb in India
7 November 2007
Mumbai:
GlaxoSmithKline's is set to launch the breast-cancer drug Tykerb in India by sometime
early next year. The
company is reported to be lining up critical care and cardio-vascular drugs for
the Indian market through two, yet-to-be formalised, in-licensing deals. According
to Dr Hasit Joshipura, vice president (South-Asia) and managing director (India)
of GlaxoSmithKline Pharmaceuticals, the company is in the process of signing deals
on the critical care and cardiovascular drugs, and should hopefully be ready with
an announcement by the end of the year. One of these drugs is reportedly a patented
drug. The in-licensing
strategy is unique to the Indian market. GSK has eight in-licensing deals in place,
which reportedly accounted for around 20 per cent of the company's growth last
year. GSK previously brought in Eisai's anti-ulcer drug Parit, and Novartis' anti-fungal
drug Terbenafine through the in-licensing route. The
oncology product Tykerb goes by the generic name is lapatinib. GSK reportedly
has received approval to market it, and is waiting for site registration, basis
which it is confident of launching the drug in India sometime in the first two
quarters of 2008. Also lined up for launch is GSK's rotavirus vaccine, related
to gastroenteritis, which will come to the Indian market almost simultaneously.
The company's
six-in-one combination vaccine - Infanrix hexa, which immunises against six diseases,
is also reportedly ready to be rolled-out during the same period, and will be
one of the products from the yet-to-be signed in-licensing deals. GSK's
break-through cervical cancer vaccine is reportedly coming to India by 2009.  According
to Dr Joshipura, Tykerb is for patients who had failed Herceptin treatment, a
medicine from Roche, and is for a very clearly defined patient group.
Other
reports on Glaxo SmithKline India Ltd Other
reports on Pharmaceuticals Other
reports on Healthcare General
reports on Marketing | 
